Merit Med Sys Inc Stock Price, News & Analysis

Merit Medical Systems, Inc. (NASDAQ: MMSI) has received FDA breakthrough device designation for its Embosphere® Microspheres for Genicular Artery Embolization (GAE) aimed at treating knee osteoarthritis. This designation accelerates the review process and enhances communication between the FDA and Merit, potentially leading to quicker market access. The Embosphere Microspheres, used in over 250,000 procedures, are recognized for their effectiveness in embolotherapy. Chairman and CEO Fred P. Lampropoulos emphasized the designation's role in expanding treatment options for patients.

Merit Medical Systems reported a strong Q4 2021, with revenue of $278.5 million, an increase of 7.9% year-over-year, and a 32% rise in GAAP EPS to $0.36. For FY21, the company achieved revenues of $1.075 billion, up 11.5%, and non-GAAP EPS of $2.37, a 43% increase. Noteworthy segments include a 18.6% revenue growth in Cardiovascular Peripheral Intervention. The company also projected a 4%-6% revenue increase for FY22. Merit's gross margin improved significantly, showcasing efficient cost management amidst inflationary pressures.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a manufacturer of disposable medical devices, will announce its financial results for Q4 and FY 2021 on February 24, 2022, after market close. The company will also provide guidance for FY 2022. An investor conference call is scheduled for the same day at 5:00 p.m. Eastern Time. Merit, established in 1987, has a global presence with over 6,700 employees and operates in various medical fields, including cardiology and oncology, serving hospitals worldwide.

Merit Medical Systems (NASDAQ: MMSI) reported Q3 2021 revenue of $267.0 million, a 9.4% increase from Q3 2020. The company achieved a GAAP EPS of $0.21, recovering from a loss of ($0.05) per share last year. Non-GAAP EPS rose to $0.52 from $0.42. The growth was fueled by strong sales in the Cardiovascular segment, particularly in Peripheral and Cardiac Interventions. Merit's non-GAAP gross margin improved to 49.1%, aided by operational efficiencies despite inflationary pressures. The company reaffirmed its full-year revenue growth guidance at 9%-10%.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced financial results for the quarter ending September 30, 2021, to be released after market close on October 28, 2021. The company will conduct a conference call for investors at 5:00 p.m. Eastern on the same day. Merit is known for its proprietary disposable devices used in various medical fields including cardiology and oncology, employing around 6,700 individuals worldwide with facilities in several countries.

The WRAPSODY FIRST Study revealed promising results for the WRAPSODY Endoprosthesis by Merit Medical Systems (MMSI), showing a 100% target lesion primary patency (TLPP) rate at 30 days and an 84.6% TLPP rate at 12 months among 46 subjects treated for arteriovenous access circuit stenosis. The study indicated a 65.9% access circuit primary patency (ACPP) rate at one year, supporting the device's safety and effectiveness. The company plans a large WAVE Study to further validate these results and pursue FDA approval.

Merit Medical Systems has launched the One-Vac™ Evacuated Drainage Bottle, a device designed to aspirate, remove, or sample body fluids. This innovative product is particularly beneficial for thoracentesis and paracentesis procedures. Its advanced features include an ergonomic handle for easy flow regulation and a durable construction to minimize spills. The launch, praised by early users, supports Merit's expanding drainage portfolio, reflecting the company's commitment to incorporating physician feedback and advancing technologies.

Merit Medical Systems, Inc. (NASDAQ: MMSI) reported Q2 2021 revenue of $280.3 million, a 28.4% increase from Q2 2020. GAAP net income was $4.9 million ($0.09/share), contrasting with a loss of ($19.1 million) last year. Non-GAAP net income reached $35.3 million ($0.62/share), up 103%. The company updated its full-year guidance, projecting net sales between $1,060 - $1,070 million, reflecting a growth of 9% - 10% year-over-year. Cash on hand increased to $70 million, while long-term debt decreased to $293 million.

Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for Q2 2021 on July 29, 2021, after market close. An investor conference call will follow at 5:00 p.m. Eastern time on the same day. The call can be accessed domestically at (844) 578-9672 and internationally at (508) 637-5656, with a live webcast available on merit.com. Founded in 1987, Merit manufactures disposable medical devices for interventional procedures and serves clients worldwide, employing about 6,500 people across multiple global locations.